Antiemetics

Cannabinoid Research Organization Announces Crowdfunding and April 2021 Benefit Concert to Celebrate Charlotte Figi’s Legacy

Retrieved on: 
Tuesday, March 2, 2021
Retail, Celebrity, General Health, Philanthropy, Music, Agriculture, Tobacco, Natural Resources, Fund Raising, Foundation, Science, Arts, Museums, Alternative medicine, Entertainment, Research, Health, Medicinal plants, Entheogens, Euphoriants, Psychoactive drugs, Health sciences, Health, Herbalism, Antiemetics, Medical cannabis, Cannabis, Tetrahydrocannabinol, Effects of cannabis

Charlotte, who had found years of relief from severe epilepsy symptoms through cannabinoid therapy, represents the millions of individuals who use cannabis and hemp to improve their health and quality of life.

Key Points: 
  • Charlotte, who had found years of relief from severe epilepsy symptoms through cannabinoid therapy, represents the millions of individuals who use cannabis and hemp to improve their health and quality of life.
  • Charlottes legacy became a foundation of education, research and patient advocacy.
  • To support the inaugural 2021 event and the community that Realm of Caring serves through cannabinoid research and education initiatives, RoC is seeking corporate sponsors 1,000 donors to contribute $1,000.
  • RoC is committed to leading-edge data collection and research while educating on novel healthcare options to empower individuals to improve their health and quality of life.

Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China

Retrieved on: 
Monday, March 1, 2021
Clinical medicine, Medicine, Branches of biology, Oncology, Antineoplastic drugs, Chemotherapy-induced nausea and vomiting, Vomiting, Cancer treatments, Antiemetics, Chemotherapy, Nausea

Starton and Haisco are preparing to launch clinical studies in chemotherapy induced nausea and vomiting (CINV), followed by additional nausea and vomiting indications.

Key Points: 
  • Starton and Haisco are preparing to launch clinical studies in chemotherapy induced nausea and vomiting (CINV), followed by additional nausea and vomiting indications.
  • Pedro Lichtinger, CEO of Starton Therapeutics, commented, Haisco is an ideal partner for our STAR-OLZ product.
  • In addition to being a respected pharmaceutical company in China, Haisco leads in antiemetic sales in China and has several antiemetics products in the market and in development.
  • Junmin Wang, Chairman of Haisco Board, commented, Haisco has built a strong profile in tumor antiemetic area.

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

Retrieved on: 
Thursday, February 25, 2021
Health sciences, Health, Medicine, Herbalism, Medicinal plants, Cannabis smoking, Pharmaceutical industry, Antiemetics, Medical cannabis, Cannabis, Cannabinoid, Clinical trial

"As a market leader in producing pure, consistent, synthetic CBD from non-cannabis plant sources, PureForm should complement Enveric's supportive care expertise.

Key Points: 
  • "As a market leader in producing pure, consistent, synthetic CBD from non-cannabis plant sources, PureForm should complement Enveric's supportive care expertise.
  • Under the terms of the agreement, PureForm will work exclusively to support Enveric's development plans in the cancer treatment and supportive care space, with Enveric owning the intellectual property.
  • Additionally, Enveric gains a guaranteed long term supply of high quality CBD, making consistent product available for preclinical and clinical studies."
  • Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients.

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Digestive diseases, Medical specialties, Clinical medicine, Antiemetics, Imidazoles, Ketones, Ondansetron, Constipation, Schizophrenia, KarXT, Schizophrenia, Karuna, PureTech Health

The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.

Key Points: 
  • The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.
  • Results published in NEJM also include data for pre-specified secondary outcome measures.
  • Rates of nausea, vomiting, and dry mouth decreased over the course of the trial, while rates of constipation remained essentially constant.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Retrieved on: 
Wednesday, February 24, 2021
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Drugs, Digestive diseases, Clinical medicine, Antiemetics, Imidazoles, Ketones, Ondansetron, Schizophrenia, Constipation, KarXT, Schizophrenia, Karuna

The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.

Key Points: 
  • The double-blind, placebo-controlled, five-week inpatient EMERGENT-1 Phase 2 trial enrolled 182 adults with an acute exacerbation of schizophrenia.
  • Rates of nausea, vomiting, and dry mouth decreased over the course of the trial, while rates of constipation remained essentially constant.
  • With the help of a dedicated treatment team, it is possible for people with schizophrenia to live full lives.
  • Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

3Chi Releases Faster Acting, Vegan Friendly Delta 8 Gummies

Retrieved on: 
Tuesday, February 23, 2021
Food and drink, Euphoriants, Drugs, Antiemetics, Appetite stimulants, Entheogens, Cannabis, Gummy candy, Tetrahydrocannabinol, Psychoactive drugs, Pectin

The industry leader in Delta 8 THC products announces the release of an improved version of their best-selling gummies.

Key Points: 
  • The industry leader in Delta 8 THC products announces the release of an improved version of their best-selling gummies.
  • 3Chi gummies now utilizes nanotechnology on its delta 8 thc oil which can reduce the time it takes to feel effects by more than 85% depending on the individual.
  • As a secondary method to accelerate effects, 3Chi is also using a softer pectin-based formula that breaks down quicker to aid in absorption of the delta 8.
  • For more information on 3Chi's delta 8 gummies or to read reviews and product testing, visit the 3Chi website .

Travis Barker Announces The Launch Of Cannabinoid Based Vegan Wellness Brand Barker Wellness Co

Retrieved on: 
Monday, February 22, 2021
Antiemetics, Appetite stimulants, Entheogens, Euphoriants, Drugs, Travis Barker, Tetrahydrocannabinol, Cannabinoid, Musicians, Psychoactive drugs

Each mindfully developed product has been used by Travis and his family on a daily basis for their own wellness purposes.

Key Points: 
  • Each mindfully developed product has been used by Travis and his family on a daily basis for their own wellness purposes.
  • Travis Barker announces launch of Barker Wellness, and new THC-free cannabinoid-infused products.
  • "I started trying lots of different CBD products in my own daily routine and saw their benefits firsthand," said Travis Barker, Founder of Barker Wellness.
  • "So I decided to create my own ideal formulas and share them with anyone looking to improve their general health.

The CBD Brand Putting Puppies First

Retrieved on: 
Monday, February 22, 2021
Drugs, Cannabinoids, Entheogens, Euphoriants, Appetite stimulants, Antiemetics, Cannabidiol, Tetrahydrocannabinol

Unfortunately, the brand that he used suffered from an issue that is rampant throughout the CBD industry: quality control.

Key Points: 
  • Unfortunately, the brand that he used suffered from an issue that is rampant throughout the CBD industry: quality control.
  • These unexpected results launched DiPietro and his fellow CBD entrepreneurs on a mission to create a dog-friendly CBD product.
  • THC-free, high-quality CBD oil is easy to get for humans as long as you do a little research beforehand.
  • However, finding a brand that truly cares about the effects that its products have on its customers' four-legged friends is a bit more difficult.

Blue Diamond Ventures Inc. New Accelerator Platform to Increase Revenue

Retrieved on: 
Monday, February 22, 2021
Herbalism, Medicinal plants, Health sciences, Branches of biology, Antiemetics, Antioxidants, Medical cannabis, Pharmaceutical sciences, Cannabis

Social Equity and Veteran Programs lead Cannabis Industry Focus in 2021

Key Points: 
  • The difference now is the industry is starting to catch up.
  • ApplicationCoaching.com went live today to provide support for the Deficiency Notices for Dispensary licenses that are due back to the State of Illinois on March 5th 2021.
  • Harvest 360 has been working for the last six months to define a cannabis license application Accelerator Program that would not only drive revenue, but in fact lower the barriers of entry at the same time.
  • This tutorial platform has received the support of multiple MSO's (larger cannabis operators) that will provide resources and support to the tutorial program in Illinois.

Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market

Retrieved on: 
Thursday, February 18, 2021
Biotechnology, FDA, Pharmaceutical, Health, Dopamine antagonists, Psychiatry, Branches of biology, Clinical medicine, Antiemetics, Typical antipsychotics, Antipsychotic, Cognitive disorders, Psychiatric diagnosis, Atypical antipsychotic, Psychosis, Dementia

Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Key Points: 
  • Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.
  • Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.
  • Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.
  • Fluphenazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).